Business Wire

STARMUS V, Host of The Stephen Hawking Medal, Hosts a Special Evening in Davos at WEF with Jean-Michel Jarre, Brian May and Luminary Scientific Panel

Share

This year, WEF was treated to a rare panel discussion bridging the fields of astronomy and music. Global CEOs and international media had the opportunity to hear from Dr. Brian May, Jean-Michel Jarre and Dr. Garik Israelian discuss STARMUS and the special connection between science and music. Flanked by a panel of renowned scientists, astronauts, and Nobel laureates, Jean-Michel Jarre introduced his groundbreaking tribute to the Apollo Missions for their 50th Anniversary.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005171/en/

WEF panel for STARMUS, Michel Mayor, Jean-Michel Jarre, Garik Israelian, and moderator Marco Larsen  ...

WEF panel for STARMUS, Michel Mayor, Jean-Michel Jarre, Garik Israelian, and moderator Marco Larsen engage with the Davos audience. Photo by: Andres Eggenberger

The esteemed panel included Swiss Astronaut Claude Nicollier, Garik Israelian, Brian May, and Michel Mayor. (Special thanks to the support from Kaspersky Labs and to the Stephen Hawking Medal for Science Communication sponsor, Omega.)

The event drew many of the world’s CEOs and music fans in Davos for The World Economic Forum eager to hear about the new musical tribute to the 50 Year Anniversary of Apollo Missions by Jean-Michel Jarre.

“For the first time, the use of ‘star sounds’ library developed by Dr. Garik Israelian will be incorporated into composed music. While it’s a relatively unknown phenomenon, it is no doubt real. I’m excited to include the actual sounds of planets and stars in this groundbreaking ode to the Apollo Missions.” - Jean-Michel Jarre.

ABOUT STARMUS V:

Fans from around the globe will descend on Zurich, Switzerland from June 24-29, 2019, to celebrate STARMUS V - the world’s most notable science and art festival. This year promises to be the most important program to date, coinciding with the 50th anniversary of the moon landings, one of science’s most important milestones. STARMUS V will also host a special ceremony announcing the 2019 Stephen Hawking Medal for Science Communication winners, supported by Omega and Kaspersky Labs.

Jean-Michel Jarre will headline a concert with “star sounds” never before heard here on earth. In addition to astronaut Michael Collins joining as the keynote, STARMUS V will host a remarkable line-up of presenters hand-selected by the STARMUS board (Stephen Hawking posthumous, May-Brit Moser, Elizabeth Blackburn, Linda Buck, Brian May, Peter Gabriel, Richard Dawkins, Alexei Leonov, Jill Tarter, Robert Williams, David Eicher, Emmanuelle Charpentier and founder, Garik Israelian). The 2019 festival STARMUS V will also feature seven of the original Apollo Mission crew, science legend and champion Bill Nye along with rock stars Brian May, Brian Eno, Steve Vai, and Rick Wakeman.

And as a special homage to the Apollo Missions and those who made them possible, Hans Zimmer will be performing a very special concert “Once Upon a Time on The Moon.”

According to Garik Israelian, STARMUS founder, the 2019 festival has been designed to ask tough questions about our place in the universe at a pivotal point in human history: “The importance of STARMUS V cannot be understated. At a time when the world retreats to isolationism, collaboration is needed to strategically present the ideas, evidence, and challenges we collectively face – and uniquely confront. We believe the biggest and best achievements of the human race are a result of that scientific collaboration.”

STARMUS V will welcome 12 Nobel laureates to the stage, as well as luminaries from the worlds of art and music, for six days of discussion, debate, and engagement across the sciences, from microbiology and biochemistry to astrophysics and neuroscience. The 2019 programme will bring together some of the most intelligent, creative, and artistic people on the planet.

Other speakers include Sir Martin Rees, Brian Cox, Emmanuelle Charpentier, and Helen Sharman.

Tickets are now officially on sale and can be purchased at www.starmus.com.

STARMUS V HONORED PARTNERS

OMEGA and The Stephen Hawking Medal:

OMEGA is a prestigious Swiss watchmaker and member of the Swatch Group Ltd. Since 1848, the brand has been synonymous with excellence, innovation, and precision, as well as a pioneering spirit, demonstrated by its achievements in sports timekeeping, the oceans, and space. In fact, since 1965, the OMEGA Speedmaster has been worn on each of NASA's manned missions including all six moon landings.

Kaspersky Lab:

Kaspersky Lab is a global cybersecurity company, which has been operating in the market for 21 years. Kaspersky Lab’s deep threat intelligence and security expertise are constantly transforming into next-generation security solutions and services to protect businesses, critical infrastructure, governments and consumers around the globe. The company’s comprehensive security portfolio includes leading endpoint protection and a number of specialized security solutions and services to fight sophisticated and evolving digital threats. Over 400 million users are protected by Kaspersky Lab technologies and we help 270,000 corporate clients protect what matters most to them. Learn more at www.kaspersky.com.

Contact information

PUBLIC, NYC
Marco Larsen
Marco@publicnewyorkcity.com
646-812-4444

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 10:00:00 EESTPress release

Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi

RISO Unveils VALEZUS, a New Brand for the Production-printing Market19.8.2019 09:00:00 EESTPress release

RISO KAGAKU CORPORATION (President & CEO: Akira Hayama; hereinafter “RISO”) announced today the launch of VALEZUS, a new brand of high-speed ink-jet printers for the production-printing market. RISO will start with successive rollouts worldwide of the new brand’s first product, the VALEZUS T2100, a high-speed, 320-page-per-minute (320-ppm) cut-sheet printer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190818005001/en/ 1 The new brand, VALEZUS One of RISO’s commanding strengths is the development of inks optimized for high-speed paper feeding and high-speed printing. This expertise enables RISO to deliver unique printing solutions serving the demand for high-volume printing. With technologies developed and cultivated in this field, RISO launches the VALEZUS, a fresh brand targeting the production-printing market. 2 The all-new VALEZUS T2100 VALEZUS T2100 The first product of the new brand, the VALEZUS T2100 is a high-speed

Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 15:00:00 EESTPress release

Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques

Merz Announces Key Governance Changes16.8.2019 12:26:00 EESTPress release

Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae

FINEOS lists on the Australian Securities Exchange16.8.2019 10:22:00 EESTPress release

FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 23:01:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom